Business
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive...
About this update from Adaptogenics Health Corp.
[{"type":"text","content":"Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results\nSEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medicine platform through scaled TCR-antigen data generation and two data partnerships. As we enter 2026, we are well positioned to drive continued growth, expand margins and achieve company-wide profitability, enabled by disciplined capital allocation and a strong financial foundation.” Fourth Quarter and Full Year 2025 Highlights Revenue for the fourth quarter and full year 2025 was $71.7 million and $277.0 million, respectively. The MRD business, which contributed 86% of revenue in the fourth quarter and 77% of revenue in the full year, grew 54% and 46% over the corresponding periods a year ago.clonoSEQ® test volume increased 43% to 30,038 tests delivered in the fourth quarter of 2025, compared to the fourth quarter 2024 and ended the year with 105,587 tests delivered, up 39% versus 2024.Received expanded Medicare coverage of clonoSEQ for recurrence monitoring in mantle cell lymphoma.Launched integration of clonoSEQ into Flatiron Health’s OncoEMR®, an industry-leading electronic medical record platform for community oncology.Implemented NovaSeq X Plus for clonoSEQ clinical sequencing.The MRD business achieved positive Adjusted EBITDA and positive cash flow.Recognized $19.5 million in MRD pharma regulatory milestone revenue in 2025.Signed two distinct, non-exclusive immune receptor data licensing agreements with Pfizer Inc. Fourth Quarter 2025 Financial Results Revenue was $71.7 million for the quarter ended December 31, 2025, representing a 51% increase from the fourth quarter in the prior ...